Top section
Top section
Both tranches price at the investor-friendly end as cloud company raises to fund expansion
Never mind that your desk had a great year, writes Craig. When it comes to getting paid, the future makes a stronger argument than the past
Top 25 shareholders and new investors participate in previously delayed offering, but some shares left over after subscriptions closed
More articles
More articles
More articles
-
Web browser Opera has bagged $115m from its Nasdaq IPO after a flood of demand made top-end pricing a certainty, according to a source close to the deal. -
Primary and secondary equity capital market investors will hope that Facebook's nightmare week is an aberration rather than an indication that tech growth is under pressure. A combination of earnings woe for other tech firms and an escalation in the trade war between US and the rest could hamper issuers' chances, writes Sam Kerr.
-
The Hong Kong Stock Exchange has put a proposal to give weighted voting rights (WVRs) to corporate entities on ice, after a tiff with its mainland counterparts and pushback from investors. But the move is not an automatic win for its rival in Singapore, which last month allowed companies to hold dual-class shares. John Loh writes.
-
Telecommunications infrastructure giant China Tower found huge demand for its multi-billion-dollar IPO this week as it kicked off bookbuilding in Hong Kong. The deal is a counter-balance to a flood of technology listings in the market this year. Jonathan Breen reports.
-
Pinduoduo, one of China’s hottest technology start-ups, sealed its $1.6bn IPO at the top end as expected, but not all American Depository Share (ADS) listings were so lucky this week as investors remained on edge.
-
Ascletis Pharma priced its Hong Kong IPO in the middle of expectations on Wednesday, raising HK$3.1bn ($400m) from the city’s inaugural biotechnology offering.
Sub-sections
shared comment list
